IN8bio, Inc. (NASDAQ:INAB – Get Free Report) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 512,000 shares, a growth of 892.2% from the March 31st total of 51,600 shares. Approximately 1.8% of the company’s stock are short sold. Based on an average daily volume of 342,700 shares, the days-to-cover ratio is currently 1.5 days.
Wall Street Analysts Forecast Growth
INAB has been the topic of a number of analyst reports. Laidlaw initiated coverage on shares of IN8bio in a report on Monday, March 18th. They set a “buy” rating and a $7.50 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective on shares of IN8bio in a report on Wednesday, April 10th.
View Our Latest Stock Report on IN8bio
Institutional Investors Weigh In On IN8bio
IN8bio Stock Performance
NASDAQ INAB traded down $0.02 during trading on Thursday, hitting $1.04. 69,734 shares of the company’s stock traded hands, compared to its average volume of 311,872. The stock has a market capitalization of $33.27 million, a price-to-earnings ratio of -1.03 and a beta of -0.01. IN8bio has a 12-month low of $0.65 and a 12-month high of $3.48. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.57 and a current ratio of 4.57. The business has a 50 day moving average of $1.13 and a 200-day moving average of $1.15.
IN8bio (NASDAQ:INAB – Get Free Report) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.05). As a group, equities research analysts anticipate that IN8bio will post -0.64 earnings per share for the current fiscal year.
IN8bio Company Profile
IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.
Read More
- Five stocks we like better than IN8bio
- Are Penny Stocks a Good Fit for Your Portfolio?
- Hasbro’s Management Made All the Right Calls This Quarter
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Dividend Capture Strategy: What You Need to Know
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.